Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin added to AID in T1D
NCT06021145Phase 4Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L) at 4 weeks. Started Apr 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06021145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021145.